Paliperidone Extended-Release

Strengths & Sizes

Note: product and packaging images are not actual size

NDC#31722-317-30
UPC Code331722317306
Imprint15

Download Label

Download HDA Sheet

Note: product and packaging images are not actual size

NDC#31722-318-30
UPC Code331722318303
Imprint3

Download Label

Download HDA Sheet

Note: product and packaging images are not actual size

NDC#31722-319-30
UPC Code331722319300
Imprint6

Download Label

Download HDA Sheet

Note: product and packaging images are not actual size

NDC#31722-320-30
UPC Code331722320306
Imprint9

Download Label

Download HDA Sheet

Indications

Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia (1.1) • Adults: Efficacy was established in three 6-week trials and one maintenance trial. (14.1) • Adolescents (ages 12-17): Efficacy was established in one 6-week trial. (14.1) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. (1.2) • Efficacy was established in two 6-week trials in adult patients. (14.2)

Product Info

Dosage FormTablet

TE CodeAB

Brand ReferenceInvega

Therapeutic CategoryAtypical antipsychotic

PronunciationPAL-ee-PER-i-DONE

Inactive Ingredientslactose monohydrate, sodium chloride, hydroxypropyl methyl cellulose, polyethylene oxides, stearic acid, FD & C Red No. 40, povidone, magnesium stearate, hydroxypropyl cellulose, cellulose acetate, polyethylene glycol, ferrosoferric oxide, propylene glycol, and titanium dioxide. The 1.5 mg and 6 mg strengths also contain iron oxide yellow and iron oxide red. The 3 mg strength also contain iron oxide red. The 9 mg strength also contain iron oxide yellow and polysorbate 80.